ΑΙhub.org
 

The fight against antibiotic resistance is growing more urgent, but artificial intelligence can help


by
20 February 2023



share this:
hundreds of pill capsules

By Vrinda Nair, Concordia University and Rachael (Ré) A Mansbach, Concordia University

Since the discovery of penicillin in the late 1920s, antibiotics have “revolutionized medicine and saved millions of lives.” Unfortunately, the effectiveness of antibiotics is now threatened by the increase of antibiotic-resistant bacteria globally.

Antibiotic-resistant infections cause the deaths of up to 1.2 million people annually, making them one of the leading causes of death.

There are several factors contributing to this crisis of resistance to antibiotics. These include overusing and misusing antibiotics in treatments. In addition, pharmaceutical companies are over-regulated and disincentivized from developing new drugs.

The World Health Organization estimates that 10 million people will die from such infections by the year 2050.

The impacts of antibiotic-resistant infections are wide-ranging. In the absence of effective prevention and treatment for bacterial infections, medical procedures such as organ transplants, chemotherapy and caesarean sections become far riskier. That’s because the severity of bacteria-related infections is increasing and untreated infections can cause a variety of health problems.

Discovering new antibiotics

Antibiotics treat illnesses by attacking the bacteria that cause them by destroying them or preventing them from reproducing.

The discovery of new antibiotics has the potential to save millions of lives. The last discovery of a novel class of antibiotics was in 1984. But it’s not easy to find a truly new antibiotic: only one out of every 15 antibiotics that enter pre-clinical development reach patients.

Developing a new drug is a costly, and often lengthy process. Also, the process of bringing novel drugs to the market and making them accessible presents formidable challenges.

This is where artificial intelligence (AI) comes into play, because it allows researchers to quickly and accurately design and assess potential drugs.

The role of AI in drug design

There has been an explosion in research in recent years in the use of AI for drug design and discovery. AI can identify new antibiotics that are structurally distinct from currently available ones and effective against a range of bacteria.

In order to discover more effective antibiotics, we need to understand the structural basis of resistance, and this understanding enables rational design principles. Developing effective second-generation antibiotics often involves optimizing first-generation drugs.

In drug development, a significant amount of money is spent developing and evaluating each generation of compounds. Researchers can use AI tools to teach computers themselves to find quick and cheap ways of discovering such novel medications.

Artificial intelligence is already showing promising results in finding new antibiotics. In 2019, researchers used a deep learning approach to identify the wide-spectrum antibiotic Halicin. Halicin had previously failed clinical trials as a treatment for diabetes, but AI suggested a different application.

Given the early identification of such a potentially strong antibiotic using artificial intelligence, a large number of such broad-spectrum antibiotics that could be effective against a range of bacteria might be identified. These drugs still need to undergo clinical trials.

Researchers at the U.S. National Institutes of Health harnessed AI’s predictive power to demonstrate AI’s potential to accelerate the process of selecting future antibiotics.

AI can be trained to screen and discover new drugs much faster — our lab at Concordia University is using this approach to identify antibiotics that would target bacterial RNA.

Algorithmic learning

Researchers design an algorithm that uses data from databases like ZINC (a collection of commercially available chemicals that can be used for virtual screening) to figure out how molecules and their properties relate. The AI models extract information from the database to analyze their patterns.

The models created by the algorithm are trained on pre-existing data. AI can rapidly sift through huge amounts of data to understand important patterns in the content or structure of a molecule.

We have seen the potential of current models to correctly predict how bacterial proteins and anti-bacterial agents would interact. But in order to maximize AI’s predictive capabilities, further refinement will still be required.

Limitations of AI

Researchers haven’t yet explored the full potential of AI models. With further developments, like increased computing power, AI can become an important tool in science. The development of AI in drug discovery research, as well as finding new antibiotics to treat bacterial infections is a work in progress.

The ability of artificial intelligence to predict and accurately identify leads has shown promising results.

Even when powered by powerful AI approaches, finding new drugs will not be easy. We need to understand that AI is a tool that contributes to research by identifying or predicting an outcome of a research question.

AI is implemented in a number of industries today, and is already changing the world. But it’s not a replacement for a scientist or doctor. AI can help the researcher to enhance or fast-track the process of drug discovery.

Even though we still have a way to go before we can fully utilize this method, there is no doubt that AI will significantly change how drugs are discovered and developed.The Conversation

Vrinda Nair, Doctoral Student in Physics, Concordia University and Rachael (Ré) A Mansbach, Assistant professor, Physics, Concordia University

This article is republished from The Conversation under a Creative Commons license. Read the original article.




The Conversation is an independent source of news and views, sourced from the academic and research community and delivered direct to the public.
The Conversation is an independent source of news and views, sourced from the academic and research community and delivered direct to the public.




            AIhub is supported by:


Related posts :



An interview with Nicolai Ommer: the RoboCupSoccer Small Size League

  01 Jul 2025
We caught up with Nicolai to find out more about the Small Size League, how the auto referees work, and how teams use AI.

Forthcoming machine learning and AI seminars: July 2025 edition

  30 Jun 2025
A list of free-to-attend AI-related seminars that are scheduled to take place between 1 July and 31 August 2025.
monthly digest

AIhub monthly digest: June 2025 – gearing up for RoboCup 2025, privacy-preserving models, and mitigating biases in LLMs

  26 Jun 2025
Welcome to our monthly digest, where you can catch up with AI research, events and news from the month past.

RoboCupRescue: an interview with Adam Jacoff

  25 Jun 2025
Find out what's new in the RoboCupRescue League this year.

Making optimal decisions without having all the cards in hand

Read about research which won an outstanding paper award at AAAI 2025.

Exploring counterfactuals in continuous-action reinforcement learning

  20 Jun 2025
Shuyang Dong writes about her work that will be presented at IJCAI 2025.

What is vibe coding? A computer scientist explains what it means to have AI write computer code − and what risks that can entail

  19 Jun 2025
Until recently, most computer code was written, at least originally, by human beings. But with the advent of GenAI, that has begun to change.

Gearing up for RoboCupJunior: Interview with Ana Patrícia Magalhães

  18 Jun 2025
We hear from the organiser of RoboCupJunior 2025 and find out how the preparations are going for the event.



 

AIhub is supported by:






©2025.05 - Association for the Understanding of Artificial Intelligence


 












©2025.05 - Association for the Understanding of Artificial Intelligence